Ginger Riley ~Eternal Optimist~

**Helping kick cancer for over 20 years** Senior PM; Standardization SME. AAOLCA survivor💙❤ former Soccer player & unapologetic FC Cincinnati supporter ⚽️🧡💙⚽

[Ginger Riley ~Eternal Optimist~ @gingerly21]

@MonopolyGO 65

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

This #ClinicalTrialsDay, the Alliance thanks the 50,000+ participants in our nearly 300 trials in recent decades. Please drop a ❤️ to show your appreciation to the scientists and courageous study participants. Learn about our 48 active trials at https://t.co/kEJkK6HGTz #CTD2026

[Mayo Clinic @MayoClinic]

Mayo Clinic Digital Pathology (MCDP) is advancing efforts to build an integrated innovation ecosystem that supports the future of pathology across clinical care and research.

The work reflects Mayo Clinic’s broader digital pathology strategy, including investments in emerging companies, expanded use of digitized pathology data and collaborations designed to improve diagnostic workflows and speed.

Learn more: https://t.co/YEsabXglaq

[The ASCO Post @ASCOPost]

🖥️ #ASCOAI: New research suggests postoperative biomarkers including NLR, urine cytology, hematuria, and NMP22 may help improve recurrence risk prediction in #bladdercancer when combined with tumor features in #AI-based models.

Explore the findings ➡️ https://t.co/DPBtmZEtxl

[Fred Hutch Cancer Center @fredhutch]

“Bringing novel therapies to patients … is really exhilarating.” — Dr. Sara Hurvitz

This #ClinicalTrialsDay, we recognize the rigor and hope behind clinical research. At Fred Hutch, every trial moves us closer to better outcomes for patients.

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

Promising results for stage III lung cancer: The AFT 46/CHIO3 trial study show combining immunotherapy and chemotherapy before surgery improves outcomes for against with locally advanced non-small cell lung cancer. @LindaMThoracic @alliance_org #LCSM https://t.co/IEq6sOoATU

[ECOG-ACRIN Cancer Research Group @eaonc]

One of the world's largest #breastcancer tissue banks is being used to study how tumors evolve. What drives an incurable late recurrence many years after the initial diagnosis? ECOG-ACRIN @SWOG & @carisls aim to find out. https://t.co/wGVgBAsEqJ #EA1241 #bcsm #TAILORx #RxPONDER

[NRG Oncology @NRGonc]

Speaking of #ClinicalTrialsDay, don't miss these upcoming podcast episodes on results presented during #ASCO26. Topics: Updated OS analysis of NRG-GY018 w/ @rne_md & the a combined analysis of prostate cancer studies w/ @krishnan_patel & @APDicker: https://t.co/PhrzD1P28w

[The ASCO Post @ASCOPost]

Don’t miss your chance to join leaders in AI-enabled cancer care, @chadinabhan and @VivekSubbiah, for a discussion on how #AI is advancing precision oncology, improving patient care, & helping clinicians make more informed treatment decisions.
Register: https://t.co/EgQ92Cw5Ca

[NRG Oncology @NRGonc]

NRG Oncology Weekly Broadcast for May 18, 2026: https://t.co/LK9ZBTynxI

[Children's Tumor Fdn @ChildrensTumor]

Join us tomorrow, May 19 at 12 PM ET for “All In for NF2” — a live CTF Town Hall. Get the most important NF2-SWN treatment updates of the year, a firsthand story from an NF2 family on treatment, and an open Q&A with experts. Register now: https://t.co/HX9FrOmmjn

#EndNF #Webinar

[ECOG-ACRIN Cancer Research Group @eaonc]

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by @kencardonaMD, aims to find out. Learn more: https://t.co/vMkhLxk8Qy #leiomyosarcoma #liposarcoma

[ECOG-ACRIN Cancer Research Group @eaonc]

Stay informed on the latest advancements in immune checkpoint inhibitors and how to tailor treatments for patients with renal cell carcinoma! Dr. Naomi Haas (@PennCancer), ECOG-ACRIN Genitourinary Cancer Committee chair, shares insights on evolving kidney cancer therapies. #kcsm

[Children’s Oncology Group @COGorg]

This National Cancer Research Month, we’re reminded that progress is powered by collaboration. United by cancer research means working together across institutions, networks, and discoveries so progress never stops.
https://t.co/898DnHeltk

[NRG Oncology @NRGonc]

UPDATED - New protocols in development lists are always available in our monthly newsletters. Here's our list as of the end of April 2026: https://t.co/Cq8i4O5Osh

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

New trial! The Alliance has a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma. Visit https://t.co/dfdhVOzGq8 to learn about Alliance A042302 led by Dr. Jennifer R. Brown of @DanaFarber. #lymsm #lymphoma

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EA2222/PUMP, led by @michael_lidsky, is a randomized phase 3[KH3.1] study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: https://t.co/xBChV6GALe

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EAA181/EQUATE, led by @myelomaMD of @mayoclinic, is testing the use of combination therapy in adult patients with newly diagnosed #MultipleMyeloma. For more information: https://t.co/Ny8oyGFFbQ #MMSM #NDMM

[Mayo Clinic Comprehensive Cancer Center @MayoCancerCare]

Abnormal headaches occur in about half of people with brain tumors. However, most headaches are not tumor related. Understanding the patterns and other brain tumor symptoms can help you know when to seek professional care. #BTAM https://t.co/JoqNwlJk9e

[Mayo Clinic @MayoClinic]

Mayo Clinic and Stanford Medicine researchers have developed the first blood test to map the complex ecosystem surrounding cancer cells, offering a more accurate way to predict which patients will benefit from immunotherapy.

Their study's findings, published in Nature, represent a major advance in precision oncology and could help guide treatment decisions across multiple cancer types and treatments.

Learn more: https://t.co/qMmzVwypL1